2014 Mystery Molecule

June

Last month, Coke decided to follow Pepsi with regards to this molecule. Can you guess what it is?

Molecule of the Month June 2014 

Brominated fatty acid
Last year, Pepsi announced that it was removing brominated vegetable oil from Gatorade, a popular sports drink. The substance had already been banned from food and drinks by the European Union because of concern over the accumulation of bromine in the body. Last month Coca-Cola announced that it was also removing the substance from Powerade, its sports drink, as well as all of its other products. Brominated fatty acids, used to keep certain ingredients in drinks from separating, will be replaced by sucrose acetate isobutyrate. Although both companies deny it, their action was probably influenced by a website set up in 2012 by a high school student in Mississippi to bring attention to the ingredient.


May

Oklahoma tried to substitute this molecule for thiopental as the first of the three-drug lethal injection cocktail last month, with disturbing results. Can you guess what it is?

Molecule of the Month May 2014 

Midazolam
This short-acting benzodiazepine has recently replaced sodium thiopental as the initial sedating drug used in executions in the U.S. Once the subject is unconscious, a muscle relaxant and potassium chloride are administered in order to stop breathing and stop the heart. Although it has apparently been used successfully in at least two executions, it failed last month, allowing the subject to regain consciousness as the additional two drugs were being injected. It is still unclear what went wrong. The prisoner did eventually die of a heart attack.


April

This month the FDA approved an easy-to-use device to inject this molecule when first responders suspect heroin overdose. Can you guess what it is?

Molecule of the Month April 2014 

Naloxone
The so-called "second chance drug", naloxone is an opioid antagonist with no agonist effect. It has been used for decades as an emergency treatment for heroin or morphine overdose as it quickly reverses depression of the respiratory system. Attorney General Eric Holder recently urged first responders to carry this molecule with them in order to be better able to resuscitate victims of overdoses. The FDA fast-tracked approval of a hand-held automatic injector of naloxone to help reduce the marked increase in deaths recently observed in the U.S.


March

This molecule is not a four-leaf clover, but any T lymphocyte "looking over" it would jump for joy. Can you guess what it is?

Molecule of the Month March 2014 

Phytohemagglutinin (PHA)
This lectin is especially plentiful in kidney beans. Its ability to agglutinate red blood cells gives it its name and also its potential toxicity when someone eats uncooked kidney beans. It is famous for inducing mitosis in T lymphocytes, and proliferation in response to PHA is used in the evaluation of immunodeficiency disorders. However, its major usefulness in the clinical laboratory is as a lymphocyte mitogen allowing the use of peripheral white blood cells for karyotype analysis as well as other cytogenetic investigations.


February

Americans like the taste of Hershey's chocolate, which uses a secret process that may produce this molecule, and other manufacturers actually add it to their recipe to enhance their sales in the U.S. Can you guess what it is?

Molecule of the Month February 2014 

Butyric acid
Many believe that Hershey's secret process involves the partial lipolysis of milk and that the production of butyric acid creates a distinct taste that differs from other types of milk chocolate. Despite the fact that the recent chocolate revolution has enhanced people's appreciation of bitter dark chocolate, Hershey's remains a market leader. We hope that your Valentine's Day was a sweet one!


January

A recent report that antibodies against this molecule helped shrink malignant melanoma tumors led Science magazine to call cancer immunotherapy the 2013 "breakthrough of the year". Can you guess what it is?

Molecule of the Month January 2014 

Programmed Death 1 (PD-1)
There are many approaches to "cancer immunotherapy" but the editors of Science focused on progress in enhancing T cell activity against epitopes on the surface of tumor cells using antibodies that prevent them from stepping on the brake. Tumor antigens (such as the classic CEA) were once considered novel tumor-specific proteins, but it soon became clear that very few (if, indeed, any) were not normal proteins whose expression was simply up-regulated in certain tumors. Because they were normal proteins, the immune system was tolerant of them. But by blocking the mechanisms that maintain tolerance, the immune system can be coaxed into attacking them. One such mechanism is a protein called PD-1 which, like another called CTLA-4, tells T cells not to react to antigen engaged by the T cell receptor. Monoclonal antibodies against these T cell "brakes" may be major cancer treatments in the future.

​ 

Page Access: